ALK Archives - Medical Conferences

NVL-655: a promising new option in pre-treated, drug-resistant ALK-mutated NSCLC

Presented By

Dr Alexander Drilon, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 1/2, ALKOVE-1

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:13

First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC

Presented By

Prof. Benjamin Solomon, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, CROWN

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:28

Higher thrombotic risk in NSCLC patient with ALK rearrangement

Presented By

Dr Hanny Al-Samkari, Massachusetts General Hospital, USA

Conference

ISTH 2020

Type

Peer-reviewed article

8 September 2020 14:41

Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 22:24

Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 21:28

site created by:

© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy

HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com